The FDA accepted a new drug application for a single inhaler that contains beclomethasone dipropionate, formoterol fumarate ...

Discover a study exploring how sugammadex reduces postoperative urinary retention in minimally invasive inguinal hernia ...

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix’s investigational intranasal potentiated oxytocin ...

We know of Alzheimer’s as a progressive disease, with the first subtle indications emerging up to 18 years before people ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ('Tonix” or the 'Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on Tonmya™ (cyclobenzaprine HCl ...

Cobenfy represents a breakthrough schizophrenia treatment with a novel mechanism, but limited long-term data requires ...

FOCUS is a randomized, double-blind, placebo-controlled crossover pilot study evaluating Tonix's investigational intranasal potentiated oxytocin products in patients with Arginine-Vasopressin Deficien ...

About 62% of nursing home residents experienced one or more drug-drug interactions (DDI) between 2018 and 2020, according to an October study published in the Journal of the American Geriatrics ...

"As Parkinson’s disease becomes more common and patients live longer, researchers are stepping up efforts to find better treatments, with nearly half of current studies focused on therapies that could ...

The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.

TNX-801 is a live virus vaccine investigational candidate, designed to provide durable protection against mpox and smallpox ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.